KARL LETKO: Open Payments
NPI 1689977019 · POCATELLO, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,125 in 57 payments from 11 companies in 2025. Trend: 2023 $742 · 2024 $992 · 2025 $1,125
Food & beverage: $1,125
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $236 |
| Vanda Pharmaceuticals Inc. | 9 | $200 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $159 |
| Otsuka America Pharmaceutical, Inc. | 7 | $156 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| Alkermes, Inc. | 4 | $71 |
| Neurocrine BioSciences, Inc. | 3 | $63 |
| ABBVIE INC. | 3 | $57 |
| E.R. Squibb & Sons, L.L.C. | 3 | $51 |
| Janssen Pharmaceuticals, Inc | 2 | $41 |
Products named: FANAPT, CAPLYTA, UZEDY, AUSTEDO XR, ABILIFY ASIMTUFII, Auvelity, REXULTI, INGREZZA.
Industry payments across ID — which companies pay providers there.
